CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Celldex Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$29.67+2.14 (+7.77%)

Close on Oct 19, 2026

Market cap: $2.31B
P/E (TTM): –
Dividend yield: –

Celldex Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Depreciation & Amortization	3.38	3.18	3.01	2.90	3.07	3.93	4.86	3.58	4.41	3.10	3.00	2.39	1.93	2.05	2.25	2.72	2.58
Stock-Based Compensation	36	34	24	16	8.95	3.92	4.55	8.08	12	15	13	6.85	4.55	2.30	2.34	2.80	3.06
Change in Accounts Receivable	-1.32	1.93	-2.28	-0.18	1.57	-0.79	2.27	-0.78	-0.10	-0.81	-0.54	0.06	-0.45	0.13	0.15	0.22	1.28
Change in Accounts Payable	11	12	9.38	3.12	3.65	1.64	-0.32	-13	-8.74	-4.97	4.88	1.45	7.24	3.76	2.08	-1.19	-2.46
Change in Unearned Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-39	-2.04
Operating Cash Flow	-211	-158	-107	-104	-61	-40	-46	-75	-100	-113	-99	-102	-68	-50	-36	-30	-30
Capital Expenditures	-2.71	-1.92	-1.82	-1.83	-1.25	-1.55	-0.73	-0.81	-1.79	-2.75	-4.88	-1.93	-4.22	-0.30	-0.51	-2.10	-0.53
Sale of Property, Plant & Equipment	–	–	–	0.07	0.03	0.06	0.02	0.34	–	–	–	–	0.02	0.22	0.07	0.08	0.85
Purchase of Investments	-385	-790	-425	-189	-390	-220	-95	-171	-171	-174	-206	-148	-112	-69	-53	-57	-9.56
Sale & Maturity of Investments	596	502	321	281	175	124	113	201	219	243	161	109	39	52	51	42	2.67
Investing Cash Flow	209	-290	-106	90	-216	-98	17	30	46	69	-50	-41	-77	-17	-2.16	-16	45
Stock Issued	–	432	216	–	270	171	16	29	51	14	189	–	296	84	36	1.01	0.67
Debt Issued	–	–	–	–	–	2.96	–	–	–	–	–	–	-11	-3.97	5.00	10	–
Debt Repaid	–	–	–	–	–	-2.96	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	2.39	441	218	4.08	272	171	16	29	51	14	193	1.17	290	80	28	11	-2.47
Net Change in Cash	0.52	-6.46	5.39	-9.71	-4.69	33	-13	-16	-2.17	-30	44	-141	145	–	–	–	–
Free Cash Flow	-214	-160	-109	-106	-62	-42	-47	-76	-102	-116	-104	-103	-72	-50	-36	-32	-30
Income Taxes Paid	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	–	–	–	–	–	–	–	–	–	–	–	–	1.21	1.38	1.56	0.60	0.16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 851.3%
Operating margin: -206220.3%
Net margin: -190220.9%
Return on equity, FY2025: -40.6%

Financial strength

Current ratio: 11.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 77.4%

Valuation

P/E ratio: –
Price to sales: 14617.17
Price to book: 3.23
Dividend yield: –